Novavax to Present at the 24th Annual Piper Jaffray Healthcare Conference
ROCKVILLE, Md., Nov. 20, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer of Novavax, will present at the 24th Annual Piper Jaffray Healthcare Conference on November 27, 2012 at 4:00pm in New York City at the New York Palace Hotel. A live webcast link for the presentation can be accessed via the Company website at www.novavax.com under Investor Info/Events.
Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biopharmaceutical company creating vaccines to address a broad range of infectious diseases worldwide. Using innovative recombinant nanoparticle technology, as well as new and efficient manufacturing approaches, the company produces vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platforms to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea and PATH. Together, these organizations support Novavax' worldwide commercialization strategy and have the global reach to create real and lasting change in the biopharmaceutical field. Additional information about Novavax is available on the company's website, www.novavax.com.